{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:39:52Z","timestamp":1789889992336,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Weill Cornell Medicine Research Reserve Fund","award":["87001468"],"award-info":[{"award-number":["87001468"]}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC240144"],"award-info":[{"award-number":["BC240144"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03631-4","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:36:24Z","timestamp":1759548984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Engineering bispecific HER2xVEGF designed ankyrin repeat proteins for targeted nanobiotechnology applications"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-9423","authenticated-orcid":false,"given":"Feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-4391","authenticated-orcid":false,"given":"Michelle S.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"3631_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319.","journal-title":"N Engl J Med"},{"key":"3631_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","volume":"29","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, et al. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat Med. 2023;29:1728\u201337.","journal-title":"Nat Med"},{"key":"3631_CR3","doi-asserted-by":"crossref","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597\u2013609.","DOI":"10.1056\/NEJMoa1914609"},{"key":"3631_CR4","first-page":"e1274","volume":"5","author":"AS Zimmer","year":"2022","unstructured":"Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. Cancer Rep (Hoboken). 2022;5:e1274.","journal-title":"Cancer Rep (Hoboken)"},{"key":"3631_CR5","doi-asserted-by":"crossref","unstructured":"Raghavendra AS, Ibrahim NK. Breast cancer brain metastasis: a comprehensive review. JCO Oncol Pract. 2024;20:1348\u201359.","DOI":"10.1200\/OP.23.00794"},{"key":"3631_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122927","author":"A Garcia-Alvarez","year":"2021","unstructured":"Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers (Basel). 2021 ; 13: 2927-48 https:\/\/doi.org\/10.3390\/cancers13122927","journal-title":"Cancers (Basel)"},{"key":"3631_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/13543784.2024.2376573","volume":"33","author":"C Edoardo","year":"2024","unstructured":"Edoardo C, Giuseppe C. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert Opin Investig Drugs. 2024;33:851\u201365.","journal-title":"Expert Opin Investig Drugs"},{"key":"3631_CR8","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, Jung KH, \u0141ugowska I, Manso L, Manzano A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358.","DOI":"10.1200\/JCO.23.02005"},{"key":"3631_CR9","doi-asserted-by":"crossref","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840\u20137.","DOI":"10.1038\/s41591-022-01935-8"},{"key":"3631_CR10","doi-asserted-by":"crossref","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30:3717\u201327.","DOI":"10.1038\/s41591-024-03261-7"},{"key":"3631_CR11","doi-asserted-by":"crossref","unstructured":"Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82:979\u201387.","DOI":"10.1007\/s40265-022-01736-w"},{"key":"3631_CR12","doi-asserted-by":"crossref","unstructured":"Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chiu Yuen Chow E, Qiu J, Song P, Yu J, Namuswe F, et al. FDA approval summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:4478\u201385.","DOI":"10.1158\/1078-0432.CCR-20-4557"},{"key":"3631_CR13","doi-asserted-by":"crossref","unstructured":"Ferrando-D\u00edez A, Felip E, Pous A, Bergamino Sirven M, Margel\u00ed M. Targeted therapeutic options and future perspectives for HER2-Positive breast cancer. Cancers (Basel) 2022 ; 14: 3305-28","DOI":"10.3390\/cancers14143305"},{"key":"3631_CR14","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1111\/1759-7714.15106","volume":"14","author":"YC Hua","year":"2023","unstructured":"Hua YC, Gao DZ, Wang KY, Ding XS, Xu WR, Li YB, Shi WW, Sun SB, Li XY. Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy. Thorac Cancer. 2023;14:3133\u20139.","journal-title":"Thorac Cancer"},{"key":"3631_CR15","doi-asserted-by":"publisher","first-page":"e960","DOI":"10.1002\/cpz1.960","volume":"4","author":"M Morselli","year":"2024","unstructured":"Morselli M, Holton TR, Pellegrini M, Yeates TO, Arbing MA. Design and construction of a designed Ankyrin repeat protein (DARPin) display library. Curr Protoc. 2024;4:e960.","journal-title":"Curr Protoc"},{"key":"3631_CR16","doi-asserted-by":"publisher","first-page":"e1805437","DOI":"10.1002\/adma.201805437","volume":"30","author":"W Yin","year":"2018","unstructured":"Yin W, Zhu J, Gonzalez-Rivas D, Okumura M, Rocco G, Pass H, Jiang G, Yang Y. Construction of a novel bispecific antibody to enhance antitumor activity against lung cancer. Adv Mater. 2018;30:e1805437.","journal-title":"Adv Mater"},{"key":"3631_CR17","doi-asserted-by":"publisher","first-page":"1352014","DOI":"10.3389\/fbioe.2024.1352014","volume":"12","author":"AV Madsen","year":"2024","unstructured":"Madsen AV, Pedersen LE, Kristensen P, Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotechnol. 2024;12:1352014.","journal-title":"Front Bioeng Biotechnol"},{"key":"3631_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pl\u00fcckthun","year":"2015","unstructured":"Pl\u00fcckthun A. Designed Ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489\u2013511.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3631_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-12-396962-0.00005-7","volume":"503","author":"R Tamaskovic","year":"2012","unstructured":"Tamaskovic R, Simon M, Stefan N, Schwill M, Pl\u00fcckthun A. Designed Ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol. 2012;503:101\u201334.","journal-title":"Methods Enzymol"},{"key":"3631_CR20","doi-asserted-by":"crossref","unstructured":"Stumpp MT, Dawson KM, Binz HK. Beyond antibodies: the DARPin(\u00ae) drug platform. BioDrugs. 2020;34(4):423\u201333.","DOI":"10.1007\/s40259-020-00429-8"},{"key":"3631_CR21","doi-asserted-by":"crossref","unstructured":"Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Pl\u00fcckthun A. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007;369:1015\u201328.","DOI":"10.1016\/j.jmb.2007.03.028"},{"key":"3631_CR22","doi-asserted-by":"crossref","unstructured":"Epa VC, Dolezal O, Doughty L, Xiao X, Jost C, Pl\u00fcckthun A, Adams TE. Structural model for the interaction of a designed Ankyrin repeat protein with the human epidermal growth factor receptor 2. PLoS One. 2013;8:e59163.","DOI":"10.1371\/journal.pone.0059163"},{"key":"3631_CR23","doi-asserted-by":"crossref","unstructured":"Rodrigues GA, Mason M, Christie LA, Hansen C, Hernandez LM, Burke J, Luhrs KA, Hohman TC. Functional characterization of Abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018;59:5836\u201346.","DOI":"10.1167\/iovs.18-25307"},{"key":"3631_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41433-019-0607-8","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (Lond). 2020;34:797\u2013801.","journal-title":"Eye (Lond)"},{"key":"3631_CR25","doi-asserted-by":"crossref","unstructured":"Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Gr\u00fctter MG, Pl\u00fcckthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol. 2004;22:575\u201382.","DOI":"10.1038\/nbt962"},{"key":"3631_CR26","doi-asserted-by":"crossref","unstructured":"Schilling J, Jost C, Ilie IM, Schnabl J, Buechi O, Eapen RS, Truffer R, Caflisch A, Forrer P. Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs. J Biol Chem. 2022;298: 101403.","DOI":"10.1016\/j.jbc.2021.101403"},{"key":"3631_CR27","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.str.2013.08.020","volume":"21","author":"C Jost","year":"2013","unstructured":"Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pl\u00fcckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure. 2013;21:1979\u201391.","journal-title":"Structure"},{"key":"3631_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s42003-021-02253-4","volume":"4","author":"JC St\u00fcber","year":"2021","unstructured":"St\u00fcber JC, Richter CP, Bell\u00f3n JS, Schwill M, K\u00f6nig I, Schuler B, Piehler J, Pl\u00fcckthun A. Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization. Commun Biology. 2021;4:762.","journal-title":"Commun Biology"},{"key":"3631_CR29","doi-asserted-by":"crossref","unstructured":"Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A, Pl\u00fcckthun A. Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K\/AKT via RAS-p110 crosstalk. Nat Commun. 2016;7: 11672.","DOI":"10.1038\/ncomms11672"},{"key":"3631_CR30","doi-asserted-by":"crossref","unstructured":"Consalvi V, Chiaraluce R, Giangiacomo L, Scandurra R, Christova P, Karshikoff A, Knapp S, Ladenstein R. Thermal unfolding and conformational stability of the recombinant domain II of glutamate dehydrogenase from the hyperthermophile Thermotoga maritima. Protein Eng. 2000;13:501\u20137.","DOI":"10.1093\/protein\/13.7.501"},{"key":"3631_CR31","doi-asserted-by":"crossref","unstructured":"Wetzel SK, Settanni G, Kenig M, Binz HK, Pl\u00fcckthun A. Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol. 2008;376:241\u201357.","DOI":"10.1016\/j.jmb.2007.11.046"},{"key":"3631_CR32","doi-asserted-by":"crossref","unstructured":"Steiner D, Forrer P, Pl\u00fcckthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol. 2008;382:1211\u201327.","DOI":"10.1016\/j.jmb.2008.07.085"},{"key":"3631_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00259-023-06407-w","volume":"51","author":"RD Houvast","year":"2024","unstructured":"Houvast RD, Badr N, March T, de Muynck L, Sier VQ, Schomann T, Bhairosingh S, Baart VM, Peeters J, van Westen GJP, et al. Preclinical evaluation of EpCAM-binding designed Ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer. Eur J Nucl Med Mol Imaging. 2024;51:2179\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3631_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169.","journal-title":"Mol Cancer"},{"key":"3631_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41698-025-00885-x","volume":"9","author":"M Mortaja","year":"2025","unstructured":"Mortaja M, Adams SR, McKay RR, Gutkind JS, Advani SJ. Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies. Npj Precision Oncol. 2025;9:97.","journal-title":"Npj Precision Oncol"},{"key":"3631_CR36","doi-asserted-by":"crossref","unstructured":"Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ. Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Cureus. 2020;12:e8921.","DOI":"10.7759\/cureus.8921"},{"key":"3631_CR37","doi-asserted-by":"crossref","unstructured":"Giugliano F, Giordano E, Gilardi L, Salimbeni BT, Zagami P, Esposito A, Marra A, Trapani D, Berton Giachetti PPM, Malagutti B, et al. Radioligand therapy in metastatic breast cancer: harnessing precision oncology. Cancer Treat Rev. 2025;136: 102940.","DOI":"10.1016\/j.ctrv.2025.102940"},{"key":"3631_CR38","first-page":"241995","volume":"65","author":"C Lizak","year":"2024","unstructured":"Lizak C, Malvezzi F, Saidi A, Mettier M, Vojackova J, Schibli R, Wullschleger S, Kaufmann Y, Lekishvili T, Riesenberg S, et al. <strong\u2009>\u2009Lead-212 Radio-DARPin therapeutic (RDT) targeting delta-like ligand 3 (DLL3) shows promising preclinical antitumor efficacy and tolerability in small cell lung cancer (SCLC)<\/strong\u2009>. J Nucl Med. 2024;65:241995\u2013241995.","journal-title":"J Nucl Med"},{"key":"3631_CR39","doi-asserted-by":"crossref","unstructured":"Wullschleger S, Saidi A, Buffet D, Stallons T, Riesenberg S, Wong A, Paladino M, Rojas F, M\u00fcller M, Herzog C, et al. Abstract 339: development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors. Cancer Res. 2025;85:339\u2013339.","DOI":"10.1158\/1538-7445.AM2025-339"},{"key":"3631_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13550-020-0599-1","volume":"10","author":"M Altai","year":"2020","unstructured":"Altai M, Garousi J, Rinne SS, Schulga A, Deyev S, Vorobyeva A. On the prevention of kidney uptake of radiolabeled DARPins. EJNMMI Res. 2020;10:7.","journal-title":"EJNMMI Res"},{"key":"3631_CR41","doi-asserted-by":"publisher","first-page":"43879","DOI":"10.1021\/acsami.9b15195","volume":"11","author":"F Chen","year":"2019","unstructured":"Chen F, Ma K, Zhang L, Madajewski B, Turker MZ, Gallazzi F, Cruickshank K, Zhang X, Jenjitranant P, Touijer KA, et al. Ultrasmall renally clearable silica nanoparticles target prostate cancer. ACS Appl Mater Interfaces. 2019;11:43879\u201387.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3631_CR42","doi-asserted-by":"crossref","unstructured":"Ma K, Mendoza C, Hanson M, Werner-Zwanziger U, Zwanziger J, Wiesner U. Control of ultrasmall sub-10 Nm ligand-functionalized fluorescent core\u2013shell silica nanoparticle growth in water. Chem Mater. 2015;27:4119\u201333.","DOI":"10.1021\/acs.chemmater.5b01222"},{"key":"3631_CR43","doi-asserted-by":"crossref","unstructured":"Ma K, Wiesner U. Modular and orthogonal post-PEGylation surface modifications by insertion enabling penta-functional ultrasmall organic-silica hybrid nanoparticles. Chem Mater. 2017;29:6840\u201355.","DOI":"10.1021\/acs.chemmater.7b02009"},{"key":"3631_CR44","doi-asserted-by":"crossref","unstructured":"Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, G\u00f6nen M, Kalaigian H, Sch\u00f6der H, et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014;6: 260ra149.","DOI":"10.1126\/scitranslmed.3009524"},{"key":"3631_CR45","doi-asserted-by":"publisher","first-page":"20021","DOI":"10.1021\/acsnano.2c05342","volume":"16","author":"F Wu","year":"2022","unstructured":"Wu F, Chen P-M, Gardinier TC, Turker MZ, Venkatesan AM, Patel V, Khor T, Bradbury MS, Wiesner UB, Adams GP, et al. Ultrasmall folate receptor alpha targeted enzymatically cleavable silica nanoparticle drug conjugates augment penetration and therapeutic efficacy in models of cancer. ACS Nano. 2022;16:20021\u201333.","journal-title":"ACS Nano"},{"key":"3631_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202370009","author":"L Zhang","year":"2023","unstructured":"Zhang L, Aragon-Sanabria V, Aditya A, Marelli M, Cao T, Chen F, Yoo B, Ma K, Zhuang L, Cailleau T, et al. Engineered ultrasmall nanoparticle drug-immune conjugates with hit and run tumor delivery to eradicate gastric cancer. Adv Ther (Weinh). 2023 ; 6: 2200209-226 https:\/\/doi.org\/10.1002\/adtp.202370009","journal-title":"Adv Ther (Weinh)"},{"key":"3631_CR47","doi-asserted-by":"crossref","unstructured":"Merten H, Brandl F, Zimmermann M, Schaefer JV, Irpinio L, Sand KMK, Nilsen J, Andersen JT, Zangemeister-Wittke U, Pl\u00fcckthun A. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. Eur J Pharm Biopharm. 2021;167:104\u201313.","DOI":"10.1016\/j.ejpb.2021.07.011"},{"key":"3631_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Zhao X, Fu K, Zhu S, Pan C, Yang C, Wang F, To KKW, Fu L. Resistance to antibody\u2013drug conjugates: A review. Acta Pharm Sinica B. 2025;15:737\u201356.","journal-title":"Acta Pharm Sinica B"},{"key":"3631_CR49","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1038\/s41467-018-06271-5","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen F, Ma K, Madajewski B, Zhuang L, Zhang L, Rickert K, Marelli M, Yoo B, Turker MZ, Overholtzer M, et al. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun. 2018;9:4141.","journal-title":"Nat Commun"},{"key":"3631_CR50","doi-asserted-by":"publisher","unstructured":"Stumpp MT, Kirkin V, Sanderson MP, Dawson KM, Legenne P. A decade of clinical experience with DARPins in oncology and virology: A systematic review. medRxiv 2025:2025.2005.2021.25328103. https:\/\/doi.org\/10.1101\/2025.05.21.25328103","DOI":"10.1101\/2025.05.21.25328103"},{"key":"3631_CR51","doi-asserted-by":"crossref","unstructured":"Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, S\u00f6rensen J, Zelchan R, et al. Phase I trial of (99m)Tc-(HE)(3)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. J Nucl Med. 2022;63:528\u201335.","DOI":"10.2967\/jnumed.121.262542"},{"key":"3631_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084246","author":"SM Deyev","year":"2024","unstructured":"Deyev SM, Oroujeni M, Garousi J, Gr\u00e4slund T, Li R, Rosly AHB, Orlova A, Konovalova E, Schulga A, Vorobyeva A, Tolmachev V. Preclinical evaluation of HER2-targeting DARPin G3: impact of albumin-binding domain (ABD) fusion. Int J Mol Sci. 2024. 25: 4246-63. https:\/\/doi.org\/10.3390\/ijms25084246.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03631-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:03:04Z","timestamp":1759593784000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03631-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03631-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this study agreed to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"627"}}